APN-541885 / Atreca - LARVOL DELTA

Atreca Announces Expansion of Preclinical Pipeline (GlobeNewswire) - "Atreca...announced a licensing agreement with Zymeworks...to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the Company’s next clinical candidate....'We are targeting one additional Investigational New Drug (IND) application per year beginning with ATRC-301 in the second half of 2023'....Atreca is advancing multiple additional lead-stage programs in oncology, including ADC leads APN-497444 and APN–959038, CD3-engager lead APN-346958, and IL-15 superagonist (SA) conjugate lead APN-541885."

IND • Licensing / partnership • Pipeline update • Oncology